UK’s MHRA To Use AI In Regulatory Review Process & RWD Analysis

The MHRA’s regulatory strategy on AI outlines key areas where this technology could be used to improve the agency’s own processes, and says that the use of AI to develop drugs will not change the questions it asks companies.

The UK’s drug regulator, the MHRA, released its strategic approach to regulating AI in medicinal products on 30 April. Much of the guidance focuses on how the MHRA plans to use AI during the regulatory assessment process for drugs, and on AI as a medical device.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Advanced Technologies